Alice Zhang is the CEO and co-founder of Verge Genomics, a company that utilizes the exponential advances in computational genomics combined with new insights into neuroscience to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease. In short, Verge aims to improve the lives of people with Alzheimer's and Parkinson's disease by using artificial intelligence (AI).

Zhang has been at the forefront of systems biology research for over seven years, at the National Cancer Institute, the Lewis-Sigler Institute for Integrative Genomics at Princeton University, and UCLA. During this time, she has co-authored multiple peer-reviewed papers in high-profile journals such as Cell and Neuron.

She graduated from Princeton University magna cum laude with high honors in Molecular Biology and is a 2012 recipient of the prestigious Paul & Daisy Soros Fellowship for New Americans. In 2010, she began training in the UCLA-Caltech MD/Ph.D. program, with a focus on neuroscience, where she spent five years investigating gene networks involved in neuro-regeneration. She was named as a Forbes 2017 30 Under 30 Featured Honoree.

UCLA, Forbes, Forbes Top Lists, Science, Research scientist Alzheimers, Alzheimer's Disease, Science & Technology, Science and Technology Professionals, Entrepreneurship: Science & Tech, Life Sciences, Healthcare Science, Health & Wellness, Healthcare, Healthcare Policy, Business of Healthcare, Technology, Innovation, Parkinson's Disease,